Improving Routine 89 Zr‐Immuno‐PET Applications: Mild Iron Removal Can Favor the Use of Fe‐DFO‐ N ‐suc‐TFP Ester Over p ‐NCS‐Bz‐DFO
Journal of Labelled Compounds and Radiopharmaceuticals · 2024
DOI: 10.1002/jlcr.4097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2024. Verfasst von Thomas E Wuensche und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Zirconium, Deferoxamine, Radioisotopes, Iron. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Marie Skłodowska-Curie, H2020 Marie Skłodowska-Curie Actions.
Abstract (Originalsprache)
A key aspect for the applicability of 89 Zr‐radioimmunoconjugates is inert modification and radiolabeling. The two commercially available bifunctional variants of the siderophore desferrioxamine (DFO), Fe‐DFO‐ N ‐suc‐TFP‐ester and p ‐NCS‐Bz‐DFO, are most often used for clinical 89 Zr‐immuno‐PET. The use of Fe‐DFO‐ N ‐suc‐TFP‐ester is advantageous with regard to higher radiolysis stability and more facile assessment of radiochemical purity as well as chelator‐to‐mAb ratio. However, not all mAbs withstand the Fe‐removal step at relatively low pH (4–4.5) using EDTA, which is needed after conjugation to allow 89 Zr labeling. In this study, it was investigated whether hydroxybenzyl ethylenediamine (HBED) or the clinically approved deferiprone (DFP) can serve as an alternative for EDTA to establish a pH‐independent mild method for Fe‐removal and thereby broaden the applicability of Fe‐DFO‐ N ‐suc‐TFP‐ester. Carrier‐added [ 59 Fe]Fe‐DFO‐ N ‐suc‐TFP‐ester was used for mAb modification to enable direct tracking of the Fe‐removal efficiency under various conditions. Whereas incomplete Fe‐removal with HBED was observed at pH 5 or higher, Fe‐removal with DFP was possible at a broad pH range (4–9). This provides a mild, pH‐independent method for Fe‐removal, improving the applicability and attractiveness of Fe‐DFO‐ N ‐suc‐TFP‐ester for 89 Zr‐mAb preparation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Brain Imaging, Amsterdam Neuroscience, Amsterdam, The Netherlands.
ORCID-Profile: Thomas E Wuensche
Förderung
- Marie Skłodowska-Curie
- H2020 Marie Skłodowska-Curie Actions
Zitieren
APA
Wuensche, T. E., Nauta, S., van Dongen, G. A. M. S., & Vugts, D. J. (2024). Improving Routine 89 Zr‐Immuno‐PET Applications: Mild Iron Removal Can Favor the Use of Fe‐DFO‐ N ‐suc‐TFP Ester Over p ‐NCS‐Bz‐DFO. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4097
Vancouver
Wuensche TE, Nauta S, van Dongen GAMS, Vugts DJ. Improving Routine 89 Zr‐Immuno‐PET Applications: Mild Iron Removal Can Favor the Use of Fe‐DFO‐ N ‐suc‐TFP Ester Over p ‐NCS‐Bz‐DFO. Journal of Labelled Compounds and Radiopharmaceuticals. 2024. doi:10.1002/jlcr.4097
BibTeX
@article{Wuensche2024,
author = {Wuensche, Thomas E and Nauta, Sabine and van Dongen, Guus A M S and Vugts, Danielle J},
title = {Improving Routine 89 Zr‐Immuno‐PET Applications: Mild Iron Removal Can Favor the Use of Fe‐DFO‐ N ‐suc‐TFP Ester Over p ‐NCS‐Bz‐DFO},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2024},
doi = {10.1002/jlcr.4097}
}
EUVIMED